These drugs are part of an emerging class of nutrient-stimulated hormone-based therapeutics, acting as incretin mimetics to target G-proteincoupled receptors like GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and glucagon
Before the FDA stepped in, GenoGenix was producing ineligible drugs (drugs not allowed under FDA rules for 503B outsourcing facilities), including peptide injectables such as 5-Amino-1MQ and NAD+, using ingredients not on the FDAs approved bulk drug substances list
The White House announced yesterday that Novo and Lilly have agreed to sell their GLP-1 obesity drugs at substantially lower prices to Medicare and Medicaid, and to lower their direct-to-consumer prices
But the molecule itself remains invisible to routine testing
Frequent, severe, or unexplained episodes should be reviewed by a doctor, as medication doses may need adjustment